Identification of claims data “signature” and economic consequences of treatment-resistant depression

Corey‐Lisle, Patricia K.; Claxton, Ami J.; Birnbaum, Howard G.; Marynchenko, Maryna; Greenberg, Paul E.; Gandhi, Gian

doi:10.1016/s0924-977x(01)80522-8

Cited by 11 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Simon et al [17] showed in their prospective longitudinal observational study of 968 patients with current depressive disorder in 6 countries (Longitudinal Investigation of Depression Outcomes (LIDO) study) that patients with partial or nonresponse had significantly higher 6-month health-care costs than those whose depression remitted (Table 5)-up to 315% higher for those with nonresponse to treatment and up to 215% higher for those with partial response to treatment. Similar results were presented by Corey-Lisle et al [68] from their database study of patients who are likely to be treatment resistant. Their analysis showed that the estimated cost for patients who are likely to be treatment resistant is almost $5,000 higher compared to patients who are unlikely to be treatment resistant.…”

Section: Response Definitionssupporting

confidence: 87%

“…Mean total monthly costs (general medical costs; depression-related costs) by number of changes in treatment: Observational database study Corey-Lisle et al [68] (US, N 5 4,186) requiring either treatment switches or augmentation or for those with partial or nonresponse to treatment compared to those in remission. The costs for nonresponders were over double the costs of those who remitted in the first year after initiation of treatment.…”

Section: Response Definitionsmentioning

confidence: 99%

“…Corey-Lisle et al [68] reported that depressed workers in the US who are likely to be treatment resistant incurred roughly double the cost associated with absenteeism compared to depressed workers who appeared responsive to treatment. Similarly, Hawthorne et al [70] reported, based on the 1998 Omnibus survey in Australia, that people with nonresponse to treatment for major depression incurred significantly higher costs due to days of reduced work or days unable to work compared to people with a partial response to treatment.…”

Section: Impact Of Partial or Nonresponse On Productivitymentioning

confidence: 99%

See 2 more Smart Citations

Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder

et al. 2009

View full text Add to dashboard Cite

Objective: To characterize the spectrum of clinical outcomes achieved with depression treatment and the associated impact on quality of life (QOL), functional status, overall well-being, health-care costs, and productivity. Sources: Electronic databases including Medline were searched for English language sources between 1995 and 2007 using key words of depression, nonresponse, partial response, and remission and QOL, functional status, utility, cost, and productivity. Study selection: Relevant abstracts were obtained for 488 references and full-text articles were reviewed that included primary data and compared outcomes by treatment response. Data were abstracted from 26 full-text articles. Data abstraction: Detailed evidence tables were prepared with the relevant data as well as information on the study design. All data abstracted were checked for accuracy. Synthesis: Treatment remitters and partial responders reported clinically and statistically significant improvements in QOL, functional status, and overall well-being compared to nonresponders. Annual health-care costs and productivity losses were significantly lower for remitters and partial responders compared to nonresponders. Conclusions: The reduced disease burden for remitters and partial responders compared to nonresponders indicates that new treatment strategies that improve the rates of response/remission with initial treatment might have value to patients and to society. Depression and Anxiety 26:83-97, 2009.

show abstract

Section: Response Definitionssupporting

confidence: 87%

Section: Response Definitionsmentioning

confidence: 99%

Section: Impact Of Partial or Nonresponse On Productivitymentioning

confidence: 99%

See 1 more Smart Citation

Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The literature on the economic consequences of treatment failure for patients with depression indicates that the direct and indirect costs of severe depression can be substantial. [7][8][9][10] In particular, depressed patients who do not respond to treatment have more than twice the resource use and costs of patients who are not treatmentresistant as well as higher indirect costs. [8,10] However, the literature on costs of severe MDD that categorize patients using actual clinical measures is sparse.…”

Section: Introductionmentioning

confidence: 99%

“…[7][8][9][10] In particular, depressed patients who do not respond to treatment have more than twice the resource use and costs of patients who are not treatmentresistant as well as higher indirect costs. [8,10] However, the literature on costs of severe MDD that categorize patients using actual clinical measures is sparse. Previous research by Kessler et al used preliminary data from the National Comorbidity Survey Replication (NCS-R) and classified survey respondents with 12-month MDD into different severity groups (mild, moderate, and severe) based on transformational rules for the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR).…”

Section: Introductionmentioning

confidence: 99%

Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance

et al. 2010

View full text Add to dashboard Cite

show abstract

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

et al. 2006

View full text Add to dashboard Cite

Based on preliminary evidence of its usefulness in treatment-resistant depression (TRD), an olanzapine/fluoxetine combination (OFC) was examined in comparison with olanzapine, fluoxetine, and venlafaxine in a TRD population. In this 12-week double-blind study, 483 subjects with unipolar, nonpsychotic TRD, with historic failure on a selective serotonin reuptake inhibitor (SSRI) and prospective failure on open-label venlafaxine, were randomized to an OFC or to an olanzapine, fluoxetine, or venlafaxine monotherapy group. Venlafaxine was continued randomly in the double-blind acute phase to explore the benefits of continuation versus switching therapy. The Montgomery-Asberg Depression Rating Scale (MADRS) total change score at end point was the primary outcome measure. The OFC group had significantly greater improvement in depressive symptoms by week 1 of treatment (MADRS mean change =-7.2, baseline =29.6), in comparison to olanzapine (-4.8, P=.03), fluoxetine (-4.7, P=.03), or venlafaxine (-3.7, P=.002) groups and maintained its statistical separation from all three monotherapy groups through week 6. At end point, the OFC group was significantly different only from the olanzapine group (-14.1 vs. -7.7, P<.001). Analysis of a subgroup of subjects who had an SSRI failure in their current depressive episode (n=334) revealed statistical separation from both olanzapine and fluoxetine (but not venlafaxine) at end point: OFC (-14.6) versus olanzapine (-9.4, P<.001) versus fluoxetine (-10.7, P=.006) versus venlafaxine (-14.7, P=.98). The OFC had a safety profile comparable to its component monotherapies (i.e., olanzapine and fluoxetine), showed a rapid onset of antidepressant effect, and was effective in this TRD sample. At the study end point, OFC, fluoxetine, venlafaxine, and low-dose OFC all appeared to be similarly effective.

show abstract

Identification of claims data “signature” and economic consequences of treatment-resistant depression

Cited by 11 publications

References 0 publications

Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder

Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder

Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

Contact Info

Product

Resources

About